Browse

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial

DC Field Value Language
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorKang, Won Ki-
dc.contributor.authorKang, Yoon-Koo-
dc.contributor.authorKim, Hugh Chul-
dc.contributor.authorJacques, Christian-
dc.contributor.authorZuber, Emmanuel-
dc.contributor.authorDaglish, Byzance-
dc.contributor.authorBoudraa, Yvane-
dc.contributor.authorKim, Won Seog-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorKim, Noe Kyeong-
dc.date.accessioned2009-11-24T04:02:13Z-
dc.date.available2009-11-24T04:02:13Z-
dc.date.issued2002-09-27-
dc.identifier.citationJpn J Clin Oncol 2002;32:248-54en
dc.identifier.issn0368-2811 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12324575-
dc.identifier.urihttp://hdl.handle.net/10371/14405-
dc.description.abstractOBJECTIVE: The aim of the present study was to confirm the efficacy and tolerability of docetaxel 75 mg/m(2) in a population of Korean patients with advanced gastric cancer. METHODS: Patients with metastatic or locally recurrent gastric cancer received docetaxel 75 mg/m(2) by intravenous infusion every 3 weeks. Objective response rate was the primary endpoint. RESULTS: Forty-five patients were enrolled. Most showed adenocarcinomas of the gastric antrum and/or body of the stomach. All showed metastases and two-thirds retained the primary tumour. Forty-four patients received at least one docetaxel infusion ('treated' population), with 40 patients evaluable for response. A total of 159 cycles (median three cycles) were administered, with mean duration of treatment 10.9 weeks. The objective response rate in the treated population was 15.9% (17.5% in the per protocol population), with stable disease in 25.0% of patients and progressive disease in 50.0%. Grade 3-4 neutropenia occurred in 36 (81.8%) patients and 36.1% of cycles. However, febrile neutropenia occurred in only two (4.5%) patients and 1.3% of cycles. Grade 3 anorexia, experienced by two patients (4.5%) and during 1.9% of cycles, was the most frequent non-haematological adverse event possibly or probably related to docetaxel. No grade 4 non-haematological events occurred. CONCLUSION: This study suggests that docetaxel 75 mg/m(2) is active in metastatic or locally recurrent adenocarcinoma with a low incidence of grade 3-4 adverse events. Docetaxel warrants further study in combination regimens for advanced gastric cancer.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.subjectAdenocarcinoma/*drug therapyen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Evaluationen
dc.subjectNeoplasm Metastasisen
dc.subjectNeoplasm Recurrence, Localen
dc.subjectNeutropenia/chemically induceden
dc.subjectPaclitaxel/administration & dosage/adverse effects/*analogs &derivatives/*therapeutic useen
dc.subjectStomach Neoplasms/*drug therapyen
dc.subject*Taxoidsen
dc.titleDocetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trialen
dc.typeArticleen
dc.contributor.AlternativeAuthor방영주-
dc.contributor.AlternativeAuthor강원기-
dc.contributor.AlternativeAuthor강윤구-
dc.contributor.AlternativeAuthor김효철-
dc.contributor.AlternativeAuthor김원석-
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor김노경-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse